Eli Lilly and Company (NYSE: LLY) today announced positive Phase 1b Heart-2 study results for VERVE-102, an investigational in vivo base editing medicine designed to durably turn off the PCSK9 gene in ...

Persons carrying loss-of-function variants of proprotein convertase subtilisin–kexin type 9 (PCSK9) have reduced levels of low-density lipoprotein (LDL) cholesterol and fewer atherosclerotic ...

PCSK9 is a co-activator of platelet function beyond its role in cholesterol homeostasis, according to research presented at ESC Congress today. The findings suggest that PCSK9 inhibitors, a new class ...

The upregulation of PCSK9 expression in endothelial cells of diabetic patients induces ubiquitination of VEGFR2 and inhibits the VEGFR2/ AKT/eNOS -ERK signaling pathway by promoting the interaction of ...

High levels of low-density lipoproteins, parcels of lipids and protein that carry cholesterol, are a leading risk factor for heart disease. Many cholesterol medications lower LDL, some of them by ...

Elevated proprotein convertase subtilisin/kexin type 9 (PCSK9) levels have been associated with adverse outcomes in patients hospitalized for sepsis. PCSK9 loss-of-function (LOF) variants area ...

A new case-control genetic study is reassuring in finding no association between a genetic proxy for pharmacologic PCSK9 inhibition and either heart failure or adverse cardiac remodeling in a large ...

How does PCSK9 function and what is the impact of this protein on cardiovascular disease? A research team coordinated by Dr. Nabil G. Seidah, researcher at the IRCM and at Université de Montréal, has ...

Barcelona, Spain - 27 Aug 2017: PCSK9 is a co-activator of platelet function beyond its role in cholesterol homeostasis, according to research presented at ESC Congress today.1 The findings suggest ...

High LDL a leading risk factor for heart disease. Many cholesterol medications lower LDL, some of them by targeting the protein PCSK9. Scientists now report on an investigation into why experiments on ...